Annals of Oncology Advance Access originally published online on May 29, 2008
Annals of Oncology 2008 19(10):1713-1719; doi:10.1093/annonc/mdn352
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
breast cancer |
Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations
1 Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
2 Department of Medical Oncology, San Bortolo Hospital, Vicenza, Italy
3 Department of Pathology
4 Department of Hematopathology
5 Department of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
* Correspondence to: Dr M. Cristofanilli, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Box 1354, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Tel: +1-713-792-2817; Fax: +1-713-794-4385; E-mail: mcristof{at}mdanderson.org
Background: Novel molecular therapies for metastatic breast cancer (MBC) are necessary to improve the dismal prognosis of this condition. Imatinib mesylate (Gleevec®) inhibits several protein tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) and c-kit, which are preferentially expressed in tumor cells. We tested the activity of imatinib mesylate in MBC with overexpression of PDGFR or c-kit. Additionally, we sought to determine the biological correlates and immunomodulatory effects.
Patients and methods: Thirteen patients were treated with Imatinib administered orally at 400 mg p.o. b.i.d. (800 mg/day), until disease progression. All patients demonstrated PDGFR-β overexpression and none showed c-kit expression.
Results: No objective responses were observed among the 13 patients treated in an intention-to-treat analysis. All patients experienced disease progression, with a median time to progression of 1.2 months. Twelve patients have died, and the median overall survival was 7.7 months. No patient had a serious adverse event. Imatinib therapy had no effect on the plasma levels of the angiogenesis-related cytokines, vascular endothelial growth factor, PDGF, b-fibroblast growth factor, and E-selectin. Immune studies showed imatinib inhibits interferon-
production by TCR-activated CD4+ T cells.
Conclusion: Imatinib as a single agent has no clinical activity in PDGFR-overexpressing MBC and has potential immunosuppressive effects.
Key words: c-kit expression, imatinib, immune-suppression, metastatic breast cancer
Received for publication February 5, 2008. Revision received April 16, 2008. Accepted for publication April 18, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Vandyke, S. Fitter, A. L. Dewar, T. P. Hughes, and A. C. W. Zannettino Dysregulation of bone remodeling by imatinib mesylate Blood, January 28, 2010; 115(4): 766 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Levina, A. Marrangoni, T. Wang, S. Parikh, Y. Su, R. Herberman, A. Lokshin, and E. Gorelik Elimination of Human Lung Cancer Stem Cells through Targeting of the Stem Cell Factor-c-kit Autocrine Signaling Loop Cancer Res., January 1, 2010; 70(1): 338 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Allington, A. J. Galliher-Beckley, and W. P. Schiemann Activated Abl kinase inhibits oncogenic transforming growth factor-{beta} signaling and tumorigenesis in mammary tumors FASEB J, December 1, 2009; 23(12): 4231 - 4243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Paulsson, T. Sjoblom, P. Micke, F. Ponten, G. Landberg, C.-H. Heldin, J. Bergh, D. J. Brennan, K. Jirstrom, and A. Ostman Prognostic Significance of Stromal Platelet-Derived Growth Factor {beta}-Receptor Expression in Human Breast Cancer Am. J. Pathol., July 1, 2009; 175(1): 334 - 341. [Abstract] [Full Text] [PDF]
|
|